Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Fred Hutchinson Cancer Center
Children's Oncology Group
Institute of Hematology & Blood Diseases Hospital, China
Astellas Pharma Inc
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
Delta-Fly Pharma, Inc.
Stanford University
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Astellas Pharma Inc
National Cancer Institute (NCI)
Guangdong Provincial People's Hospital
University of Washington
Sanofi
Children's Oncology Group
Fred Hutchinson Cancer Center
Amgen
Thomas Jefferson University
Servier
Medical College of Wisconsin
Technische Universität Dresden
University of Pittsburgh
Wake Forest University Health Sciences
Arog Pharmaceuticals, Inc.
University of Washington
Arog Pharmaceuticals, Inc.
Sumitomo Pharma America, Inc.
Fred Hutchinson Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
University of Washington
Ohio State University Comprehensive Cancer Center
University of Kentucky
Goethe University
Cornerstone Pharmaceuticals
Rush University Medical Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Children's Oncology Group
New York Medical College
The University of Hong Kong
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
Sumitomo Pharma Co., Ltd.
University of Washington
German CLL Study Group
University of Washington
Rush University Medical Center
University of Birmingham